Department Metrics

• Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (Contact):Rejniak, K.,PI (MPI):Pilon-Thomas, S.
• Characterizing Cytotoxic Therapy Induced Shifts in the Cost-to-Benefit Ratio of High Ploidy
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Andor, N.
• Development of Adoptive T-Cell Therapy in Bladder Cancer Incorporating Patient-Specific Tumor Microenvironment
  Award Number:
  Sponsor: US Army
  PI:Rejniak, K.
• Modeling the Role and Regulation of Reactive Stroma in Breast Ductal Carcinoma Microinvasions
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Rejniak, K.
• The Delta Ecology of NSCLC Treatment
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (Contact):Anderson, A.,PI (MPI):Gatenby, R.,Project PI:Marusyk, A.
• The Delta Ecology of NSCLC Treatment - Diversity Supplement
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (Contact):Anderson, A.,PI (MPI):Gatenby, R.

CLINICAL TRIAL 20117
A Phase 1/2 Study of Regn5678 (Anti-psmaxcd28) with Cemiplimab (Anti-pd-1) in Patients with Metastatic Castration-Resistant Prostate Cancer
Condition: Genitourinary
Intervention: Cemiplimab (); REGN2810 (Cemiplimab); REGN5678 (); Sarilumab (); [18]F-DCFPyL ()

CLINICAL TRIAL 22003
A Phase II Randomized Study of Sipuleucel-T with or without Continuing New Hormonal Agents (NHA) in Metastatic Prostate Cancer with PSA Progression while on NHA and LHRH Analog
Condition: Genitourinary
Intervention: Abiraterone (); Apalutamide (); Enzalutamide (Xtandi); Provenge (Sipuleucel-T); Sipuleucel-T (); prednisone ()

CLINICAL TRIAL 22254
A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination with Pembrolizumab in Subjects with Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2
Condition: Genitourinary
Intervention: Disitamab Vedotin (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 22350
A Phase I/II Open Label Study to Evaluate the Safety, Cellular Kinetics, and Efficacy of AZD0754, a Chimeric Antigen Receptor (CAR) T-cell Therapy Directed Against STEAP2, in Adult Participants with Metastatic Prostate Cancer: APOLLO
Condition: Genitourinary
Intervention: AZD0754 (); AZD2287 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 22623
HERO Trial: Phase I Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents in localized bladder cancer
Condition: Genitourinary
Intervention: AMP-514 (Durvalumab); Durvalumab (); FK228 (Romidepsin); MEDI4736 (Durvalumab); Romidepsin ()

CLINICAL TRIAL 23692
A Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ACE-232 in Patients with Metastatic Castration-Resistant Prostate Cancer (CRPC)
Condition: Genitourinary
Intervention: ACE-232 ()

• Luddy K, Newman H, Gravon J, Robertson-Tessi M, Gatenby R. Radiopharmaceutical Therapy and Immunotherapy Combinations Utilizing Cancer Evolution and Computational Modeling in Metastatic Prostate Cancer. PET Clin. 2026 Jan.21(1):169-180. Pubmedid: 41136296.
• Scibilia KR, Gallagher K, Masud MA, Robertson-Tessi M, Gatenbee CD, West J, Llamas P, Prabhakaran S, Gallaher J, Anderson ARA. Mathematical Oncology: How Modeling Is Transforming Clinical Decision-Making. Cancer Res. 2025 Dec.85(24):4866-4879. Pubmedid: 41105675. Pmcid: PMC12614879.
• Gatenby RA, Anderson ARA, Brown JS, Gallaher J, Krolick J, Lemanne D. Directed Evolution Restored Castrate Sensitivity in a Patient With Castrate Resistant Metastatic Prostate Cancer. Prostate. 2025 Dec.85(16):1562-1567. Pubmedid: 40878050.
• Gravenmier C, Marzban S, Tang YH, Gillis N, Shah BD, Moscinski LC, Zhang L, West J. Cell state transitions drive the evolution of disease progression in B-lymphoblastic leukemia. Cancer Res Commun. 2025 Nov. Pubmedid: 41295979.
• Olumoyin K, Rejniak K. Modeling Adoptive Cell Therapy in Bladder Cancer from Sparse Biological Data using PINNs. ArXiv. 2025 Oct. Pubmedid: 41281226. Pmcid: PMC12633144.
• Hosny N, Shen K, Zhao Y, Qu J, Sun Y, Butler G, Amend S, Hammarlund EU, Gatenby R, Brown J, Pienta KJ, Phan TV, Boyer-Paulet S, Li S, Austin RH. Protocol to model tumor hypoxia in vitro using real-time phosphorescence-based sensing of O2 gradients generated by metastatic cancer cells. STAR Protoc. 2025 Oct.6(4):104163. Pubmedid: 41150854. Pmcid: PMC12597275.
• Beck R, Tagal V, Amin S, Bakhoum SF, Maley C, Verhaak RGW, Gomes AP, Andor N. Energetics of whole genome doubling and genomic instability. Cancer Lett. 2025 Oct.630:217878. Pubmedid: 40517938.
• Gallagher K, Strobl MAR, Anderson ARA, Maini PK. Deriving Optimal Treatment Timing for Adaptive Therapy: Matching the Model to the Tumor Dynamics. Bull Math Biol. 2025 Sep.87(10):146. Pubmedid: 40921859. Pmcid: PMC12417256.
• West J, Desai B, Strobl M, Gallaher J, Robertson-Tessi M, Marusyk A, Anderson ARA. Evolutionary antifragile therapy. bioRxiv. 2025 Sep. Pubmedid: 41000654. Pmcid: PMC12458151.
• Arabzadeh M, Tang YH, Colin-Leitzinger C, Marzban S, Walgenbach D, Morganti S, Mahaganapathy V, Harper E, Teng M, Kresovich JK, Washington I, Parsons HA, Garber JE, West J, Ganesan S, Khiabanian H, Gillis N. Clonal Hematopoiesis Dynamics and Evolutionary Fitness During Cancer Treatment Impact Clinical Outcomes. medRxiv. 2025 Sep. Pubmedid: 40950448. Pmcid: PMC12424905.
• Luddy KA, West J, Robertson-Tessi M, Desai B, Ojeda A, Newman H, Estrella V, Bursell TM, Barrett S, O'Sullivan J, Marignol L, Gatenby RA, Brown JS, Anderson AR, O'Farrelly C. Evolutionary Double-Bind Treatment Using Radiation Therapy and Natural Killer Cell-Based Immunotherapy in Prostate Cancer. Int J Radiat Oncol Biol Phys. 2025 Sep. Pubmedid: 40998270.
• Milne A, Marusyk A, Maini PK, Anderson ARA, Picco N. The role of environmentally mediated drug resistance in facilitating the spatial distribution of residual disease. Commun Biol. 2025 Aug.8(1):1189. Pubmedid: 40783466. Pmcid: PMC12335614.
• Tyczynska Weh M, Kumar P, Marusyk V, Marusyk A, Basanta D. The adaptive state determines the impact of mutations on evolving populations. Proc Natl Acad Sci U S A. 2025 Jul.122(26). Pubmedid: 40569384. Pmcid: PMC12232665.
• Veith T, Beck R, Tagal V, Li T, Alahmari S, Cole J, Hannaby D, Kyei J, Yu X, Maksin K, Schultz A, Lee H, El Naqa I, Eschrich S, Ji HP, Diaz A, Andor N. CLONEID: A Framework for Longitudinal Integration of Phenotypic and Genotypic Data to Monitor and Steer Subclonal Dynamics. bioRxiv. 2025 Jul. Pubmedid: 40631300. Pmcid: PMC12236826.
• Beck RJ, Andor N. Local Adaptive Mapping of Karyotype Fitness Landscapes. bioRxiv. 2025 Jun. Pubmedid: 40667108. Pmcid: PMC12262491.
• Hosny N, Shen K, Zhao Y, Qu J, Sun Y, Butler G, Amend S, Hammarlund EU, Gatenby R, Brown J, Pienta KJ, Phan TV, Boyer-Paulet S, Li S, Austin RH. Phosphorescence-based sensing reveals size-dependent survival and motility of metastatic prostate cancer cells in self-generated hypoxia. iScience. 2025 May.28(5):112325. Pubmedid: 40475852. Pmcid: PMC12139443.
• Gatenby RA, Teer JK, Tsai KY, Brown JS. Parallel and convergent dynamics in the evolution of primary breast and lung adenocarcinomas. Commun Biol. 2025 May.8(1):775. Pubmedid: 40399443. Pmcid: PMC12095661.
• Chamseddine I, Kambara M, Bhatt P, Pilon-Thomas S, Rejniak KA. Optimizing the Efficacy of Vaccine-Induced Immunotherapy in Melanomas. Bull Math Biol. 2025 May.87(7):86. Pubmedid: 40434675. Pmcid: PMC12279038.
• Desai B, Miti T, Prabhakaran S, Miroshnychenko D, Henry M, Marusyk V, Kumar P, Ozakinci H, Gatenbee C, Bui M, Boyle TA, Scott J, Altrock PM, Haura E, Anderson ARA, Basanta D, Marusyk A. Multifactorial stroma-mediated resistance is a major contributor to residual disease under targeted therapies in lung cancers. Res Sq. 2025 Apr. Pubmedid: 40313737. Pmcid: PMC12045365.
• Bhattacharya R, Avdieiev SS, Bukkuri A, Whelan CJ, Gatenby RA, Tsai KY, Brown JS. The Hallmarks of Cancer as Eco-Evolutionary Processes. Cancer Discov. 2025 Apr.15(4):685-701. Pubmedid: 40170539.
• Gallagher K, Strobl MAR, Anderson ARA, Maini PK. Deriving Optimal Treatment Timing for Adaptive Therapy: Matching the Model to the Tumor Dynamics. medRxiv. 2025 Apr. Pubmedid: 40236415. Pmcid: PMC11998818.
• Nowicka Z, Rentzeperis F, Tagal V, Teer JK, Ilter D, Beck RJ, Cole JP, Forero Pinto AM, Tejero JD, Scanu E, Veith T, Dominguez-Viqueira W, Maksin K, Carrillo-Perez FM, Gevaert O, Xu X, Karreth FA, Abdalah MA, Fiandaca G, Pasetto S, Prabhakaran S, Schultz A, Ojwang' AME, Barnholtz-Sloan JS, Farinhas JM, Gomes AP, Katira P, Andor N. Interactions between Ploidy and Resource Availability Shape Clonal Evolution in Glioblastoma. Cancer Res. 2025 Apr.85(8):1544-1559. Pubmedid: 39933186.
• Veith T, Beck R, Brown JS, Andor N. Inverse Game Theory Characterizes Frequency-Dependent Selection Driven by Karyotypic Diversity in Triple Negative Breast Cancer. bioRxiv. 2025 Mar. Pubmedid: 40196548. Pmcid: PMC11974723.
• Hammarlund EU, Bukkuri A, Norling MD, Islam M, Posth NR, Baratchart E, Carroll C, Amend SR, Gatenby RA, Pienta KJ, Brown JS, Peters SE, Hancke K. Benthic diel oxygen variability and stress as potential drivers for animal diversification in the Neoproterozoic-Palaeozoic. Nat Commun. 2025 Mar.16(1):2223. Pubmedid: 40118825. Pmcid: PMC11928486.
• Park MA, Whelan CJ, Ahmed S, Boeringer T, Brown J, Carson TL, Crowder SL, Gage K, Gregg C, Jeong DK, Jim HSL, Judge AR, Mason TM, Parker N, Pillai S, Qayyum A, Rajasekhara S, Rasool G, Tinsley SM, Schabath MB, Stewart P, West J, McDonald P, Permuth JB. Correction: Park et al. Defining and Addressing Research Priorities in Cancer Cachexia through Transdisciplinary Collaboration. Cancers 2024, 16, 2364. Cancers (Basel). 2025 Mar.17(6). Pubmedid: 40149388. Pmcid: PMC11941415.
• Avasthi KK, Choi JW, Glushko T, Manley BJ, Yu A, Park JY, Brown JS, Pow-Sang J, Gatenby R, Wang L, Balagurunathan Y. Extracellular Microvesicle MicroRNAs and Imaging Metrics Improve the Detection of Aggressive Prostate Cancer: A Pilot Study. Cancers (Basel). 2025 Feb.17(5). Pubmedid: 40075682. Pmcid: PMC11898942.
• Permuth J, Park M, Davis E, Alhassan S, Arnoletti J, Basinski T, McKee A, Bloomston M, Carson T, de Castria TB, Chen DT, Cortizas E, Crowder S, Delgado MG, Douglas W, Fleming J, Hodul P, Huguet K, Jiang K, Kim DW, Koomen J, Luthra A, Malafa M, Menon A, Morales R, Merchant N, Meredith K, Mo Q, Molina-Vega M, Moreno-Urazan L, Olumoyin K, Parker N, Pimiento J, Rasool G, Rejniak K, Sansil S, Sparks L, Stewart P, Tassielli A, Teer J, Tran DV, Trevino J, Velanovich V, Whelan C, Jeong D, Judge S, Judge A. Race-based differences in serum biomarkers for cancer-associated cachexia in a diverse cohort of patients with pancreatic ductal adenocarcinoma. Res Sq. 2025 Feb. Pubmedid: 39989973. Pmcid: PMC11844656.
• Nagy MZ, Plaza-Rojas LB, Boucher JC, Kostenko E, Austin AL, Tarhini AA, Chen Z, Du D, Ojwang' AME, Davis J, Obermayer A, Rejniak KA, Shaw TI, Guevara-Patino JA. Effector T cells under hypoxia have an altered transcriptome similar to tumor-stressed T cells found in non-responsive melanoma patients. J Immunother Cancer. 2025 Feb.13(2). Pubmedid: 40010774.
• Li R, Villa NY, Yu X, Johnson JO, Borjas G, Dhillon J, Moran-Segura CM, Kim Y, Francis N, Dorman D, Powers JJ, Sexton WJ, Spiess PE, Poch MA, Zemp L, Gilbert SM, Zhang J, Pow-Sang JM, Anderson ARA, Li T, Wang X, Grass GD, Burke JM, Dinney CPN, Rodriguez PC, Jain RK, Mulé JJ, Conejo-Garcia JR. Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial. Nat Med. 2025 Jan.31(1):176-188. Pubmedid: 39521884.
• Chamseddine I, Kambara M, Bhatt P, Pilon-Thomas S, Rejniak KA. Optimizing the Efficacy of Vaccine-Induced Immunotherapy in Melanomas. bioRxiv. 2025 Jan. Pubmedid: 39829889. Pmcid: PMC11741369.
• Bukkuri A, Andersson S, Mazariegos MS, Brown JS, Hammarlund EU, Mohlin S. Cell types or cell states? An investigation of adrenergic and mesenchymal cell phenotypes in neuroblastoma. iScience. 2024 Dec.27(12):111433. Pubmedid: 39687008. Pmcid: PMC11648246.
• Mukherjee UA, Hockings H, Counsell N, Patel A, Narayanan P, Wilkinson K, Dhanda H, Robinson K, McNeish I, Anderson ARA, Miller R, Gourley C, Graham T, Lockley M. Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensi. BMJ Open. 2024 Dec.14(12):e091262. Pubmedid: 39806715. Pmcid: PMC11667365.